Elixir Lyrics

Recent Elixir News:
Elixir Medical Corporation Announces Outstanding Two-Year Results from the EXCELLA BD Randomized Clinical Trial for ... - Fri, 24 May 2013
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its
Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable ... - Tue, 21 May 2013
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent six-month clinical trial results today from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System.
Elixir Medical Receives CE Mark Approval for the Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System - Wed, 15 May 2013
Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark approval for its DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System.
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting ... - Wed, 08 May 2013
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration to initiate patient enrollment in the EXCELLA III clinical trial in the United States at up to 50 institutions with conditions to be addressed in parallel.
Elixir's DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System receives CE Mark approval - Wed, 15 May 2013
Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark approval for its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System.